Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

08.01.25 22:11 Uhr

Werte in diesem Artikel

CARLSBAD, Calif., Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Wednesday, January 15, 2025.

Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Ionis Investor Contact: D. Wade Walke, Ph.D., ir@ionis.com – 760-603-2331
Ionis Media Contact: Hayley Soffer, media@ionis.com – 760-603-4679

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302346348.html

SOURCE Ionis Pharmaceuticals, Inc.

Ausgewählte Hebelprodukte auf Ionis Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ionis Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Ionis Pharmaceuticals Inc

Wer­bung

Analysen zu Ionis Pharmaceuticals Inc

DatumRatingAnalyst
07.08.2018Ionis Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
18.08.2017Ionis Pharmaceuticals OutperformBMO Capital Markets
09.08.2017Ionis Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
14.07.2017Ionis Pharmaceuticals OutperformBMO Capital Markets
28.12.2016Ionis Pharmaceuticals OutperformBMO Capital Markets
DatumRatingAnalyst
07.08.2018Ionis Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
18.08.2017Ionis Pharmaceuticals OutperformBMO Capital Markets
09.08.2017Ionis Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
14.07.2017Ionis Pharmaceuticals OutperformBMO Capital Markets
28.12.2016Ionis Pharmaceuticals OutperformBMO Capital Markets
DatumRatingAnalyst
22.09.2015ISIS Pharmaceuticals Equal WeightBarclays Capital
10.02.2009ISIS Pharmaceuticals ErsteinschätzungCitigroup Corp.
11.08.2008ISIS Pharmaceuticals neutralCowen and Company, LLC
28.04.2008ISIS Pharmaceuticals DowngradeNeedham & Company, LLC
18.04.2008ISIS Pharmaceuticals DowngradeLeerink Swann LLC
DatumRatingAnalyst
18.12.2012ISIS Pharmaceuticals underperformJefferies & Company Inc.
08.11.2012ISIS Pharmaceuticals underperformJefferies & Company Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Ionis Pharmaceuticals Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"